AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 212 min read$CAPR

/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

Original reporting
prnewswire.com
Published Aug 21, 2026, 5:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 6:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/ — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CAPRBearishMed
01

Why it matters

The filing explains the 64% price drop and creates a new catalyst for investors to consider lead‑plaintiff status.

02

Market read

The lawsuit adds material legal risk to CAPR, driving further downside and offering a lead‑plaintiff opportunity.

03

What to watch

Potential settlement terms or FDA clarification could mitigate downside.

Relevance 7/10Novelty 8/10Timing: lead‑plaintiff deadline Sep 28 2026

Background

Capricor Therapeutics (NASDAQ: CAPR) announced a securities‑fraud class action alleging misstatements about its lead product Deramiocel and FDA BLA process.

Company-level read

Ticker impact

$CAPRBearishHigh confidence
Context

Securities fraud class action filed against Capricor Therapeutics alleging false statements about its FDA BLA, causing a 64% stock drop.

Expected impact

Expect continued weakness; short‑bias until resolution or settlement.

Evidence & confidence

Legal exposure and recent 64% plunge indicate heightened risk; investors may seek lead‑plaintiff status, adding volatility.

Market effects

Sector

Biotech sector may see heightened scrutiny on FDA filing disclosures.

Regional

U.S. biotech investors likely to reassess risk exposure.

Global

Limited to investors holding CAPR or similar small‑cap biotech stocks.

Counterpoint

What could challenge this read

If the lawsuit stalls, the stock could rebound on short‑covering.

Key entities

  • company
    Capricor Therapeutics, Inc.

    Biotech firm developing Deramiocel.

  • law_firm
    Kessler Topaz Meltzer & Check, LLP

    Plaintiff‑side firm leading the securities‑fraud lawsuit.

Read at source← All news

Related articles

AUG 24
$CAPRMedAI 8/10

Why is Capricor Therapeutics stock rallying today?

Capricor Therapeutics (CAPR) stock rose 2.6% after the FDA extended its review period for Deramiocel to November 22, 2026, due to new data submission. Shares initially surged to $8.015 but retreated amid broader market declines and regulatory concerns. Analysts have mixed views, with Cantor Fitzgerald targeting $28. The stock's 52-week range is $2.96 to $40.37.

investing.com2 min
AUG 24
$CAPRMed

Capricor Therapeutics stock surges on FDA review extension

Capricor Therapeutics (CAPR) shares rose 29% after the FDA extended the review period for its Deramiocel BLA to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data supporting a refined indication for Duchenne muscular dystrophy. The FDA accepted the amendment, citing significant unmet medical need.

investing.com2 min
AUG 24
$CAPRLow

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics (CAPR) faces a class action lawsuit for alleged securities violations. The DJS Law Group claims the company made false statements regarding its clinical data analysis and FDA agreement for Deramiocel. Shareholders who bought shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm by September 28, 2026, to discuss potential recovery.

prnewswire.com1 min
AUG 21
$CAPRLow

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

prnewswire.com2 min
AUG 20
$CAPRLowAI 8/10

Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges misstatements about the company's lead product candidate and FDA compliance. The stock dropped 64% on July 27, 2026, following FDA briefing documents. Investors have until September 28, 2026, to seek lead plaintiff status.

globenewswire.com2 min